
Nigeria, Africa bear 25% of global disease burden — Expert
An Executive Consultant with over 25 years of clinical research and data management experience in the United States of America, Dr Bisi Adekoya, has disclosed that Nigeria—and Africa generally—shares 25 percent of the global disease burden.
Adekoya, who is the Founder of a clinical research company called NxtCRO, made this disclosure at a symposium titled Clinical Trials in Underserved Populations: Barriers and Strategies for Inclusion, held on Thursday at the University of Lagos.
She explained that disease burden comprises deaths (mortality), disability (years lived with illness), economic cost, and overall reduction in quality of life.
Similarly, the expert lamented that more than half of pharmaceutical ingredients in Nigeria, and 100 percent of vaccines, are imported.
She pointed out that Nigeria is a country at risk if it cannot produce and consume pharmaceutically.
'It has been gathered that Africa shares 25 percent of the global disease burden.
'Disease burden comprises deaths (mortality), disability (years lived with illness), economic cost, and overall reduction in quality of life.
'In the same vein, it is shocking that Nigeria imports 85–100 percent of pharmaceutical ingredients and 100 percent of vaccines (biopharmaceuticals), and 85 percent of marketed medications.
'Nigeria is a country currently at risk if we cannot produce and consume pharmaceutically,' she said.
Meanwhile, Adekoya called on the Federal Government to look inwards towards the local production of pharmaceutical products.
She also advocated for the conduct of clinical trials within the country and the collection of local data for the survival and advancement of the country's health sector.
Copyright © 2022 Nigerian Tribune Provided by SyndiGate Media Inc. (Syndigate.info).
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Zawya
14 hours ago
- Zawya
Nigeria, Africa bear 25% of global disease burden — Expert
An Executive Consultant with over 25 years of clinical research and data management experience in the United States of America, Dr Bisi Adekoya, has disclosed that Nigeria—and Africa generally—shares 25 percent of the global disease burden. Adekoya, who is the Founder of a clinical research company called NxtCRO, made this disclosure at a symposium titled Clinical Trials in Underserved Populations: Barriers and Strategies for Inclusion, held on Thursday at the University of Lagos. She explained that disease burden comprises deaths (mortality), disability (years lived with illness), economic cost, and overall reduction in quality of life. Similarly, the expert lamented that more than half of pharmaceutical ingredients in Nigeria, and 100 percent of vaccines, are imported. She pointed out that Nigeria is a country at risk if it cannot produce and consume pharmaceutically. 'It has been gathered that Africa shares 25 percent of the global disease burden. 'Disease burden comprises deaths (mortality), disability (years lived with illness), economic cost, and overall reduction in quality of life. 'In the same vein, it is shocking that Nigeria imports 85–100 percent of pharmaceutical ingredients and 100 percent of vaccines (biopharmaceuticals), and 85 percent of marketed medications. 'Nigeria is a country currently at risk if we cannot produce and consume pharmaceutically,' she said. Meanwhile, Adekoya called on the Federal Government to look inwards towards the local production of pharmaceutical products. She also advocated for the conduct of clinical trials within the country and the collection of local data for the survival and advancement of the country's health sector. Copyright © 2022 Nigerian Tribune Provided by SyndiGate Media Inc. (

Zawya
17 hours ago
- Zawya
Mobile clinics enhance access to health care services in Niger
In Niger, West Africa's largest country by land surface, access to health care services is a major challenge. Just one in two people has access to health services. One of the ways to bridge the gap is through mobile clinics in remote areas and deploying medical teams from health districts to villages. Among the main beneficiaries of the initiative are pregnant women. They are now able to receive emergency assistance and care for timely detection of any complications. Mariama, 42, who suffered complications after a fall, is grateful to have received care thanks to a mobile clinic. Ordinarily, she would have had to travel for a whole day to the nearest district health facility in Dosso town from her home in the southwest of Niger. 'As I was preparing to make the trip, I was informed of a mobile clinic in our area, and I went there the very next day. The team midwife consulted me and discovered that I had premature rupture of membranes,' she recounts. Under the initiative 'mobile clinic teams visit villages that are hard to reach for health care in general and reproductive health services for women and children in particular,' says Nafissatou Salifou Panga, midwife and Reproductive Health Focal Point for Dosso health district. 'It is a huge relief that pregnant women are able to benefit from care that detects risks in time and provides them with appropriate care.' Thanks to the care and follow-up she received, Mariama gave birth safely. Like Mariama, 267 pregnant women in Dosso and Filingué districts benefited from mobile clinic consultations in 2024. In all, almost 28 000 people were consulted and 3767 women received reproductive health services. Around 16 000 women were sensitized by community outreach teams on reproductive, maternal and neonatal health in the two districts. In Mariama's case, the community health teams shared awareness messages that enabled her to be informed in time of the arrival of the mobile clinic. By reaching populations far from health centres, the mobile clinic initiative also helps to improve health coverage at district and national levels. For example, the maternal mortality ratio fell from 441 per 100 000 live births in 2017 to 350 in 2023, according to World Bank data. Dr Aissatou Laouali, in charge of the reproductive health programme with World Health Organization (WHO) in Niger, says the initiative helping to accelerate efforts towards health for all. 'For vulnerable populations, rapid access to quality health care is vital. Through these initiatives, we hope to move forward in solving the challenges particularly faced by mothers and children living in remote areas." To ensure service quality, the district, in collaboration with WHO, organizes planning meetings and field supervision trips and supports the Ministry of Health and Public Hygiene in improving maternal and child health, in particular by providing technical guidelines, standards and protocols for reproductive, maternal and child health. Other support includes training health workers and improving the facilities in mother-and-child health centres, regional and district hospitals, and integrated health centres. WHO also supports training of health providers to ensure quality of care and health surveillance to curb maternal mortality. Niger has maintained the mobile clinics introduced earlier. In 2024, with support from WHO and donor financing, operational and medical equipment and supply needs of the mobile clinics were catered for. Additionally, 56 health workers and community outreach officers were trained in reproductive health in Dosso and Filingué districts. 'I was very satisfied with the care provided … I encourage the women in my community to come to the mobile clinic for any health problem,' says Mariama. 'If I hadn't gone to the centre after the incident, I would have had an infection with the risk of losing my baby." Distributed by APO Group on behalf of WHO Regional Office for Africa.


Zawya
18 hours ago
- Zawya
The Department of Health – Abu Dhabi and Abbot unite to manufacture pharmaceuticals locally in Abu Dhabi
ABU DHABI, UAE /PRNewswire/ -- During BIO International Convention in Boston USA, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership to localise manufacturing of pharmaceuticals in Abu Dhabi and advance digital health solutions. Leveraging Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare ecosystem. H.E. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: "Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences. By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community." The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development initiative. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant said: "Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi. Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE." Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 to 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI).